¸£Àû¼§

The aims of our research are to uncover the cellular and molecular mechanisms that predispose to systemic and long-term anti-tumor immunity and the mechanisms that drive resistance to immunotherapy.

Our research aims to understand the function of DNA methylation in the biology of human CD4+ T-cells, and use this knowledge to dissect its role in disease.

WCMM at LiU focuses on the medicine-technology interface, and build upon our existing strengths in research within medical technology, materials science and bioengineering.

We develop and implement medical image analysis methods using deep learning. Our medical focus areas are cancer, orthopedics and body composition analysis using multiple image and data modalities.

This project is focusing on Quantitative MRI of the brain. Quantitative MRI is a novel and promising technique for diagnose or prognose disease and to determine the choice of therapy, or to monitor the result of the chosen therapy.

The 6-year, €70 million project called BIGPICTURE, will herald a new era in pathology and take AI development in pathology to the next level: we will develop the world’s biggest repository for sharing of pathology data.

The aim of our research is to identify, validate and implement genetic markers or other biomarkers to predict drug metabolism or drug effects.

Molecular genetic analysis of endocrine tumors (thyroid, parathyroid, adrenal, neuroendocrine): pathogenesis and development of metastases.

In addition to cellular studies, we study TPMT and the various genetic variants using recombinant protein. We use biophysical techniques to study the difference in protein stability and drug affinity between TPMT and other genetic varieties.

Our research is within the field of Drug research and Onco-pharmacology. Our aim is to identify drugs with new mechanisms of action, and try to develop drug candidates for clinical use.